SCYNEXIS Inc.: SCYNEXIS Announces Launch of Initial Public Offering of Common Stock

Tickers: SCYX
SCYNEXIS Announces Launch of Initial Public Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C., Mar. 24, 2014 - Drug discovery and development company SCYNEXIS, Inc., today announced that it plans to commence a road show on March 24, 2014 for the proposed initial public offering of shares of its common stock. SCYNEXIS has filed a registration statement with the Securities and Exchange Commission to offer 4,230,800 shares of its common stock to the public. The initial public offering price is currently expected to be between $12.00 and $14.00 per share. The underwriters have an option to purchase an additional 634,620 shares of common stock at the initial public offering price less the underwriting discount, within 30 days from the date of the offering.

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Wal-Mart Stores, Inc.
An application has been made to list the common stock of SCYNEXIS on the NASDAQ Global Market under the symbol "SCYX."

RBC Capital Markets and Canaccord Genuity are serving as joint bookrunning managers. In addition, JMP Securities is participating as lead manager in the offering. The offering of SCYNEXIS common stock will be made only by means of a prospectus. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

When available, a copy of the preliminary prospectus relating to the proposed initial public offering may be obtained on the SEC EDGAR Filings Website: http://www.sec.gov/. Until then, you may obtain more information by contacting RBC Capital Markets, Attention: Prospectus Department, Three World Financial Center, 200 Vesey Street 8th Floor, New York, NY 10281, telephone (877) 822-4089 or Canaccord Genuity Inc., Attn: Syndicate Department, 99 High Street, 12th Floor, Boston, MA 02110, telephone (617) 371-3900.

About SCYNEXIS

SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as a novel oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. In addition, we have clinical and preclinical programs based on the use of cyclophilin inhibitors to treat viral diseases, as well as contract research and development services primarily in the field of animal health. www.scynexis.com.

Company:
Amanda Mancuso - Chief of Staff
SCYNEXIS, Inc.
amanda.mancuso@scynexis.com
Tel: +1 919 544 8663
Media Relations:
Cory Tromblee - MacDougall Biomedical Communications
ctromblee@macbiocom.com
Tel: +1 781 235 3060
distributed by

This noodl was issued by SCYNEXIS Inc. and was initially posted at www.scynexis.com. It was distributed, unedited and unaltered, by noodls on 2014-04-03 14:51:19 CET. The issuer is solely responsible for the accuracy of the information contained therein.